Xu T - Search Results

1

Synthesis and biological evaluation of 4-(pyridin-4-oxy)-3-(3,3-difluorocyclobutyl)-pyrazole derivatives as novel potent transforming growth factor-β type 1 receptor inhibitors.

Xu G, Zhang Y, Wang H, Guo Z, Wang X, Li X, Chang S, Sun T, Yu Z, Xu T, Zhao L, Wang Y, Yu W. Xu G, et al. Among authors: xu t. Eur J Med Chem. 2020 Jul 15;198:112354. doi: 10.1016/j.ejmech.2020.112354. Epub 2020 Apr 29. Eur J Med Chem. 2020. PMID: 32387837

2

[The exploration of VEGF-B methylation in the nasal polyp].

Tan HY, Bai WL, Wang XW, Xu TT. Tan HY, et al. Among authors: xu tt. Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2017 Oct 5;31(19):1482-1484;1491. doi: 10.13201/j.issn.1001-1781.2017.19.005. Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2017. PMID: 29798099 Chinese.

3

Vascular endothelial growth factor over-expressed mesenchymal stem cells-conditioned media ameliorate palmitate-induced diabetic endothelial dysfunction through PI-3K/AKT/m-TOR/eNOS and p38/MAPK signaling pathway.

Xu T, Lv Z, Chen Q, Guo M, Wang X, Huang F. Xu T, et al. Biomed Pharmacother. 2018 Oct;106:491-498. doi: 10.1016/j.biopha.2018.06.129. Epub 2018 Jul 11. Biomed Pharmacother. 2018. PMID: 29990837

4

CircRNAs in anticancer drug resistance: recent advances and future potential.

Xu T, Wang M, Jiang L, Ma L, Wan L, Chen Q, Wei C, Wang Z. Xu T, et al. Mol Cancer. 2020 Aug 17;19(1):127. doi: 10.1186/s12943-020-01240-3. Mol Cancer. 2020. PMID: 32799866 Free PMC article. Review.

5

Advances in Understanding the LncRNA-Mediated Regulation of the Hippo Pathway in Cancer.

Wang M, Xu T, Feng W, Liu J, Wang Z. Wang M, et al. Among authors: xu t. Onco Targets Ther. 2021 Apr 7;14:2397-2415. doi: 10.2147/OTT.S283157. eCollection 2021. Onco Targets Ther. 2021. PMID: 33854336 Free PMC article. Review.

6

Case Report: Long-Term Survival With Anlotinib in a Patient With Advanced Undifferentiated Large-Cell Lung Cancer and Rare Tonsillar Metastasis.

Xu T, Wei C, Zou X, Lu B, Wang Z. Xu T, et al. Front Oncol. 2021 Jun 24;11:680818. doi: 10.3389/fonc.2021.680818. eCollection 2021. Front Oncol. 2021. PMID: 34249723 Free PMC article.

7

HEY1-mediated cisplatin resistance in lung adenocarcinoma via epithelial-mesenchymal transition.

Gao J, Li Y, Zou X, Lei T, Xu T, Chen Y, Wang Z. Gao J, et al. Among authors: xu t. Med Oncol. 2022 Nov 17;40(1):18. doi: 10.1007/s12032-022-01886-7. Med Oncol. 2022. PMID: 36396748

8

Anlotinib combined with osimertinib reverses acquired osimertinib resistance in NSCLC by targeting the c-MET/MYC/AXL axis.

Lei T, Xu T, Zhang N, Zou X, Kong Z, Wei C, Wang Z. Lei T, et al. Among authors: xu t. Pharmacol Res. 2023 Feb;188:106668. doi: 10.1016/j.phrs.2023.106668. Epub 2023 Jan 18. Pharmacol Res. 2023. PMID: 36681369 Free article.

9

Fractured vertebra antedisplacement reconstruction technique: a feasible treatment choice for posttraumatic thoracolumbar kyphosis.

Xu T, Wang S, Fang H, Wu H, Li F. Xu T, et al. J Neurosurg Spine. 2024 May 24:1-9. doi: 10.3171/2024.3.SPINE231174. Online ahead of print. J Neurosurg Spine. 2024. PMID: 38788235

10

Inhibition of stem-like cells proliferation and programmed cell death-ligand 1 expression by blocking transforming growth factor-β1 signaling pathway in angiosarcoma.

Li Z, Jin S, Lyu Y, Guo N, Li Q, Cai W, Du J, Qiu J, Xu T, Zhao K, Pang L. Li Z, et al. Among authors: xu t. Arch Dermatol Res. 2024 May 24;316(6):209. doi: 10.1007/s00403-024-02927-z. Arch Dermatol Res. 2024. PMID: 38787445 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

12,032 results

Search Page